Molgramostim + Placebo + Molgramostim Open-label
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Pulmonary Alveolar Proteinosis
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Trial Timeline
May 19, 2021 → May 30, 2027
NCT ID
NCT04544293About Molgramostim + Placebo + Molgramostim Open-label
Molgramostim + Placebo + Molgramostim Open-label is a phase 3 stage product being developed by Savara for Autoimmune Pulmonary Alveolar Proteinosis. The current trial status is active. This product is registered under clinical trial identifier NCT04544293. Target conditions include Autoimmune Pulmonary Alveolar Proteinosis.
What happened to similar drugs?
0 of 12 similar drugs in Autoimmune Pulmonary Alveolar Proteinosis were approved
Approved (0) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04544293 | Phase 3 | Active |
Competing Products
20 competing products in Autoimmune Pulmonary Alveolar Proteinosis